Results 71 to 80 of about 9,772 (228)
Migraine: Diagnosis, treatment and understanding c1960-2010 [PDF]
, 2014 seminar transcriptThere are around eight million migraine sufferers in the UK today. This Witness Seminar looked at the last 50 years of research into the diagnosis and treatment of the condition and the changing attitudes of the medical profession ...
Overy, C, Tansey, EM
core
Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley +1 more source
Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine
Drug Design, Development and Therapy, 2016 Gianni Allais, Chiara Benedetto Department of Surgical Sciences, Women’s Headache Center, University of Turin, Turin, Italy Abstract: Migraine is a common neurovascular disorder, affecting millions of people worldwide.
Allais G, Benedetto C
doaj
Headache and pregnancy. a systematic review [PDF]
, 2017 This systematic review summarizes the existing data on headache and pregnancy with a scope on clinical headache phenotypes, treatment of headaches in pregnancy and effects of headache medications on the child during pregnancy and breastfeeding, headache ...
A. Negro +9 more
core +1 more source
Migraine and the Risk of Dementia in the General Population
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract INTRODUCTION Migraine and dementia are prevalent disorders with high societal impact; however, research regarding their association remains inconsistent. METHODS We analyzed 6888 participants from the prospective Rotterdam Study. Migraine status was assessed (2006–2011) via validated questionnaire.
Cevdet Acarsoy +4 more
wiley +1 more source
Treatment of migraine and tension-type headache in Croatia [PDF]
, 2010 The aim of this study was to assess the treatment patterns of migraine and tension-type headache in the Croatian population. Analysis included the proportion of patients who were taking specific antimigraine therapy and the number of tablets per attack ...
Arijana Lovrenčić Huzjan +4 more
core +1 more source
Arthritis &Rheumatology, Volume 78, Issue 4, Page 985-992, April 2026.Objectives The aim of this study is to generate hypotheses about unknown drugs associated with the onset or worsening of Raynaud's phenomenon (RP) and to explore their potential pathophysiologic mechanisms through a mixed disproportionality/clustering analysis from the World Health Organization (WHO) pharmacovigilance database.
Alex Hlavaty +4 more
wiley +1 more source
Безопасность и риск фармакотерапииINTRODUCTION. Lasmiditan, a new selective 5-HT1F receptor agonist (approved by FDA in 2019), relieves migraine attacks via neuronal inhibition and acts in the central and peripheral nervous systems.
I. A. Mazerkina, R. N. Alyautdin
doaj +1 more source
The triptan formulations: a critical evaluation Formulações dos triptanos: avaliacão crítica
Arquivos de Neuro-Psiquiatria, 2003 The migraine-specific triptans have revolutionized the treatment of migraine and are usually the drugs of choice to treat a migraine attack in progress.
Marcelo E. Bigal +3 more
doaj +1 more source
Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study [PDF]
, 2012 The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study.
B +15 more
core +1 more source